Tau Reduction in Hippocampal GABAergic Interneurons
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Individuals with the apolipoprotein E4 (apoE4) allele are at higher risk for developing Alzheimer's disease due to impaired tau protein function, leading to neurofibrillary tangles and cognitive decline, with existing treatments failing to effectively address the underlying neuronal dysfunction.
Innovation Solution
A method involving the reduction of tau levels in GABAergic interneurons in the hippocampus, achieved through administering interfering nucleic acids or genetically modified stem cells that decrease tau production, thereby enhancing interneuron functionality and cognitive function.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing treatments are used for apoE4-associated disorders, then general Alzheimer's disease symptoms are addressed, but underlying neuronal dysfunction in GABAergic interneurons is not effectively treated
Solution Approach 1:
The invention applies local quality by specifically targeting GABAergic interneurons in the hilus of the hippocampus with tau-lowering therapy, rather than treating the brain globally. This localized approach addresses the specific neuronal population that is most affected in apoE4 carriers, improving treatment reliability for this specific dysfunction while sparing other brain regions from unnecessary intervention.
Solution Approach 2:
The invention segments the Alzheimer's disease pathology into distinct neuronal populations, identifying GABAergic interneurons as a specific target. By segmenting the treatment approach to focus on this particular cell type rather than treating all neurons uniformly, the therapy can more effectively address the specific neuronal dysfunction characteristic of apoE4-associated disorders.
2Reliability
If tau levels are reduced in GABAergic interneurons, then interneuron functionality is improved, but the complexity of targeted delivery increases
Solution Approach 1:
The invention uses an intermediary approach by employing agents that can cross the blood-brain barrier and selectively accumulate in GABAergic interneurons. These intermediary molecules mediate the delivery of tau-lowering therapy to the specific target population, improving interneuron functionality while avoiding the need for complex direct injection or surgical delivery systems.
3Object-affected harmful factors
If tau protein function is impaired, then neurofibrillary tangles form, but cognitive decline progresses
Solution Approach 1:
The invention applies the blessing in disguise principle by converting the harmful accumulation of tau protein into a beneficial therapeutic target. By developing tau-lowering agents that specifically reduce tau levels in GABAergic interneurons, the therapy transforms the pathological tau accumulation that causes neurofibrillary tangles into a treatable condition, thereby preventing cognitive decline and improving outcomes in apoE4-associated disorders.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach increases the number and functionality of GABAergic interneurons, ameliorates cognitive deficits, and reduces neurofibrillary tangles, effectively addressing apoE4-associated neurological disorders by improving memory and cognitive functions.
Implementation Method 1
administering interfering nucleic acids or genetically modified stem cells that decrease tau production
Data Source
AI summary
The present disclosure provides a method of increasing the functionality of a GABAergic interneuron in the hilus of the hippocampus of an individual having at least one apolipoprotein E4 (apoE4) allele. The method generally involves reducing tau levels in the interneuron.